FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,670 | -53.8% | 42,297 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $194,170 | -15.1% | 40,792 | +1.7% | 0.00% | -50.0% |
| Q1 2023 | $228,678 | -42.4% | 40,119 | +2.0% | 0.00% | -33.3% |
| Q4 2022 | $396,749 | -55.1% | 39,321 | -0.4% | 0.00% | -50.0% |
| Q3 2022 | $884,000 | -8.3% | 39,463 | +1.4% | 0.01% | -14.3% |
| Q2 2022 | $964,000 | -38.3% | 38,907 | -3.4% | 0.01% | -22.2% |
| Q1 2022 | $1,562,000 | -38.1% | 40,296 | -6.6% | 0.01% | -30.8% |
| Q4 2021 | $2,524,000 | -4.1% | 43,131 | -2.9% | 0.01% | -7.1% |
| Q3 2021 | $2,633,000 | -32.5% | 44,422 | -1.1% | 0.01% | +7.7% |
| Q2 2021 | $3,899,000 | +1.8% | 44,928 | -3.3% | 0.01% | 0.0% |
| Q1 2021 | $3,831,000 | -4.2% | 46,464 | +5.6% | 0.01% | -13.3% |
| Q4 2020 | $4,001,000 | +133.7% | 43,998 | +2.7% | 0.02% | +87.5% |
| Q3 2020 | $1,712,000 | +30.3% | 42,835 | +11.8% | 0.01% | +33.3% |
| Q2 2020 | $1,314,000 | +64.7% | 38,306 | +6.7% | 0.01% | +50.0% |
| Q1 2020 | $798,000 | +7.4% | 35,913 | -5.5% | 0.00% | +33.3% |
| Q4 2019 | $743,000 | +44.8% | 37,988 | +15.0% | 0.00% | +50.0% |
| Q3 2019 | $513,000 | -24.0% | 33,034 | -0.7% | 0.00% | -33.3% |
| Q2 2019 | $675,000 | -0.7% | 33,263 | -14.0% | 0.00% | 0.0% |
| Q1 2019 | $680,000 | +32.8% | 38,679 | -3.1% | 0.00% | +50.0% |
| Q4 2018 | $512,000 | -5.7% | 39,933 | +19.9% | 0.00% | 0.0% |
| Q3 2018 | $543,000 | +48.0% | 33,317 | +2.9% | 0.00% | +100.0% |
| Q2 2018 | $367,000 | +21.9% | 32,374 | +4.9% | 0.00% | 0.0% |
| Q1 2018 | $301,000 | +91.7% | 30,864 | +20.2% | 0.00% | 0.0% |
| Q4 2017 | $157,000 | +55.4% | 25,683 | +0.5% | 0.00% | – |
| Q3 2017 | $101,000 | +31.2% | 25,561 | +8.1% | 0.00% | – |
| Q2 2017 | $77,000 | -92.0% | 23,650 | +23788.9% | 0.00% | – |
| Q1 2014 | $964,000 | +55.0% | 99 | 0.0% | 0.00% | – |
| Q4 2013 | $622,000 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |